Charlotte's Web Holdings (CWBHF) Total Non-Current Liabilities (2020 - 2026)
Charlotte's Web Holdings' (CWBHF) quarterly Total Non-Current Liabilities came in at $77.6 million in Q1 2026, up 13.37% year-on-year from $68.5 million in Q1 2025, and up 13.07% on a QoQ basis from $68.7 million in Q4 2025.
Charlotte's Web Holdings (CWBHF) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Charlotte's Web Holdings (CWBHF) has 7 years of Total Non-Current Liabilities data on file, last reported at $77.6 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 13.37% year-over-year to $77.6 million in Q1 2026; TTM through Mar 2026 was $77.6 million, a 13.37% increase from a year earlier, with the FY2025 full-year figure at $68.7 million, down 2.51% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $77.6 million, up from $68.7 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for CWBHF reached as high as $94.0 million in Q2 2024 and fell as low as $31.7 million in Q3 2022.
- Historically, Total Non-Current Liabilities has averaged $64.9 million across 5 years, with a median of $70.4 million in 2024.
- Across the five-year window, Total Non-Current Liabilities retreated 22.26% in 2025 and gained 13.37% in 2026, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $31.7 million in 2022, then surged by 131.71% to $73.3 million in 2023, then fell by 3.99% to $70.4 million in 2024, then slipped by 2.51% to $68.7 million in 2025, then gained by 13.07% to $77.6 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $77.6 million in Q1 2026, $68.7 million in Q4 2025, and $63.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Charlotte's Web Holdings | 41.51 Mn | 36.32 Mn | 5.20 Mn | 77.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 77.63 Mn |
| Dec 31, 2025 | 68.65 Mn |
| Sep 30, 2025 | 63.48 Mn |
| Jun 30, 2025 | 73.05 Mn |
| Mar 31, 2025 | 68.47 Mn |
| Dec 31, 2024 | 70.42 Mn |
| Sep 30, 2024 | 72.92 Mn |
| Jun 30, 2024 | 93.97 Mn |
| Mar 31, 2024 | 75.48 Mn |
| Dec 31, 2023 | 73.34 Mn |
| Sep 30, 2022 | 31.65 Mn |
| Jun 30, 2022 | 37.09 Mn |
| Mar 31, 2022 | 37.66 Mn |
| Dec 31, 2021 | 41.06 Mn |
| Dec 31, 2020 | 52.24 Mn |